Patients scheduled for minimally invasive mitral valve replacement. Each patient will be
treated with intravenous (i.v.) oxycodone - patient-controlled analgesia (PCA). Half of the
patients will be randomly allocated to Erector Spinae Plane (ESP) blockade group.